3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
1
Coronavirus Infections
1
COVID-19
1
Interventions
BNT162 Vaccine
2
2019-nCoV Vaccine mRNA-1273
2
tocilizumab
1
sotrovimab
1
heterologous prime boost COVID-19 vaccination
1
cilgavimab and tixagevimab drug combination
1
Therapeutics
1
Specimen Handling
1
Sodium Chloride
1
Radiotherapy
1
Losartan
1
Janus Kinase Inhibitors
1
Ivermectin
1
Interleukin-7
1
Hydroxychloroquine
1
HuMax-IL8
1
Ad26COVS1
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
COVID-19
×
Ivermectin
×
Clear all
NCT04447235
2022-08-09
TITAN
Instituto do Cancer do Estado de São Paulo
Phase 2
Terminated
77 enrolled